2022 MIPS Quality Measures (eCQMs)

Quality IdMeasure NameMeasure TypeMeasure Description
3762022 MIPS Measure #376: Functional Status Assessment for Total Hip ReplacementeCQMPercentage of patients 18 years of age and older who received an elective primary total knee arthroplasty (TKA) and completed a functional status assessment within 90 days prior to the surgery and in the 270-365 days after the surgeryView
3752022 MIPS Measure #375: Functional Status Assessment for Total Knee ReplacementeCQMPercentage of patients 18 years of age and older who received an elective primary total hip arthroplasty (THA) and completed a functional status assessment within 90 days prior to the surgery and in the 270-365 days after the surgeryView
4752022 MIPS Measure #475: HIV ScreeningeCQMPercentage of patients aged 15-65 at the start of the measurement period who were between 15-65 years old when tested for HIVView
4762022 MIPS Measure #476: Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic HyperplasiaeCQMPercentage of patients with an office visit within the measurement period and with a new diagnosis of clinically significant Benign Prostatic Hyperplasia who have International Prostate Symptoms Score (IPSS) or American Urological Association (AUA) Symptom Index (SI) documented at time of diagnosis and again 6-12 months later with an improvement of 3 pointsView
0122022 MIPS Measure #12: Primary Open-Angle Glaucoma (POAG): Optic Nerve EvaluationeCQMPercentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma (POAG) who have an optic nerve head evaluation during one or more visits within 12 monthsView
2392022 MIPS Measure #239: Weight Assessment and Counseling for Nutrition and Physical Activity for Children/AdolescentseCQMPercentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period.View
3102022 MIPS Measure #310: Chlamydia Screening for WomeneCQMPercentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement periodView
TBD2022 MIPS Measure # TBD: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancereCQMPercentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.View
1072022 MIPS Measure #107: Adult Major Depressive Disorder (MDD): Suicide Risk AssessmenteCQMAll patient visits during which a new diagnosis of MDD or a new diagnosis of recurrent MDD was identified for patients aged 18 years and older with a suicide risk assessment completed during the visitView
3182022 MIPS Measure # 318: Falls: Screening for Future Fall RiskeCQMPercentage of patients 65 years of age and older who were screened for future fall risk during the measurement periodView
3782022 MIPS Measure #378: Children Who Have Dental Decay or CavitieseCQMPercentage of children, 6 months - 20 years of age at the start of the measurement period, who have had tooth decay or cavities during the measurement periodView
3792022 MIPS Measure #379: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including DentistseCQMPercentage of children, 6 months - 20 years of age, who received a fluoride varnish application during the measurement periodView
3822022 MIPS Measure #382: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk AssessmenteCQMPercentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide riskView
2812022 MIPS Measure #281: Dementia: Cognitive AssessmenteCQMPercentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month periodView
0092022 MIPS Measure #9: Anti-depressant Medication ManagementeCQMPercentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported.View
4722022 MIPS Measure #472: Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic FractureeCQMPercentage of female patients 50 to 64 years of age without select risk factors for osteoporotic fracture who received an order for a dual-energy x-ray absorptiometry (DXA) scan during the measurement periodView
3662022 MIPS Measure #366: Follow-Up Care for Children Prescribed ADHD Medication (ADD)eCQMPercentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.View